about
Site-specific role of catechol-O-methyltransferase in dopamine overflow within prefrontal cortex and dorsal striatum2(S)-(Cycloalk-1-enecarbonyl)-1-(4-phenyl-butanoyl)pyrrolidines and 2(S)-(aroyl)-1-(4-phenylbutanoyl)pyrrolidines as prolyl oligopeptidase inhibitorsBinding kinetics and duration of in vivo action of novel prolyl oligopeptidase inhibitors.Genetically Modified Caco-2 Cells With Improved Cytochrome P450 Metabolic Capacity.Similar molecular descriptors determine the in vitro drug permeability in endothelial and epithelial cells.Prolyl endopeptidase is involved in cellular signalling in human neuroblastoma SH-SY5Y cells.Comparison of in vitro cell models in predicting in vivo brain entry of drugs.Brief isoflurane anesthesia regulates striatal AKT-GSK3β signaling and ameliorates motor deficits in a rat model of early-stage Parkinson's disease.Brain pharmacokinetics of ganciclovir in rats with orthotopic BT4C glioma.Brain uptake of ketoprofen-lysine prodrug in rats.Synthesis and in-vitro/in-vivo evaluation of orally administered entacapone prodrugs.Re-evaluation of the role of P-glycoprotein in in vitro drug permeability studies with the bovine brain microvessel endothelial cells.4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors.Substrate-dependent, non-hyperbolic kinetics of pig brain prolyl oligopeptidase and its tight binding inhibition by JTP-4819.Dicarboxylic acid bis(L-prolyl-pyrrolidine) amides as prolyl oligopeptidase inhibitors.Pharmacodynamic response of entacapone in rats after administration of entacapone formulations and prodrugs with varying bioavailabilities.Conformationally rigid N-acyl-5-alkyl-L-prolyl-pyrrolidines as prolyl oligopeptidase inhibitors.Lack of increased oxidative stress in catechol-O-methyltransferase (COMT)-deficient mice.Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.Dicarboxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oligopeptidase inhibitors and three-dimensional quantitative structure-activity relationship of the enzyme-inhibitor interactions.Comparison of the effects of deramciclane, ritanserin and buspirone on extracellular dopamine and its metabolites in striatum and nucleus accumbens of freely moving rats.Comparison of seven different anesthesia protocols for nicotine pharmacologic magnetic resonance imaging in rat.Disease-Induced Alterations in Brain Drug Transporters in Animal Models of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.Dose-response effect of acute phencyclidine on functional connectivity and dopamine levels, and their association with schizophrenia-like symptom classes in rat.Combined ipsilateral limb use score as an index of motor deficits and neurorestoration in parkinsonian rats.Prolyl oligopeptidase inhibition decreases extracellular acetylcholine levels in rat hippocampus and prefrontal cortex.The effect of prolyl oligopeptidase inhibition on extracellular acetylcholine and dopamine levels in the rat striatum.Comparison of phencyclidine-induced spatial learning and memory deficits and reversal by sertindole and risperidone between Lister Hooded and Wistar rats.Unpredictable rotational responses to L-dopa in the rat model of Parkinson's disease: the role of L-dopa pharmacokinetics and striatal dopamine depletion.Brain pharmacokinetics of two prolyl oligopeptidase inhibitors, JTP-4819 and KYP-2047, in the rat.Free fatty acid receptor 1 (GPR40) agonists containing spirocyclic periphery inspired by LY2881835.An introduction of a pyridine group into the structure of prolyl oligopeptidase inhibitorsSynthesis and in vitro/in vivo evaluation of novel oral N-alkyl- and N,N-dialkyl-carbamate esters of entacaponeKYP-2047 penetrates mouse brain and effectively inhibits mouse prolyl oligopeptidaseDiscovery of polar spirocyclic orally bioavailable urea inhibitors of soluble epoxide hydrolase
P50
Q28249776-FBD5B0B5-64F2-4B53-83AD-915D7B95A93BQ28282683-46A0D18A-75A0-4318-8507-C52113FBDA55Q34651535-5D7E8B88-35E3-4371-9CA2-2E0D1EADD798Q38794808-5A985C75-967F-4524-8E60-FE36994A9929Q39321917-C7B2D416-47C9-4F25-B8F5-1C506D5C2D71Q39559618-F5498B70-F46B-4A06-A4ED-CFAD60011261Q39648248-095DA95A-BEF5-4C1A-8B10-FE96EC251EBDQ41551976-453B2298-FE1C-421C-AC19-09D29E015AD0Q42182796-3257E5AA-F6F6-448A-A656-FC9279D4AB77Q42930696-C230EDB7-D912-4449-95FF-D2CA3324BB22Q43815270-41752283-DAAF-494D-B0A0-9BE071EC6848Q43879475-35745897-4A8E-4EF4-9A93-873FB6239239Q43976101-4E400F8B-5677-4852-9C77-06C4DE682C72Q44082415-D5ACEC79-2CD3-40A9-B0C2-9F0198123336Q44142686-0891B06E-FA42-4BC6-917D-A17D6FA92865Q44196249-36B9DD9D-3662-43E2-A146-B90FF7757EAEQ44539034-6C13D98B-7F35-4C2E-B339-73430BDD0F43Q45065973-E91DB9BF-0380-4A4E-AA49-0BE220A0D20FQ45951082-FF7AF2A2-386C-46C4-9B5A-DBEDB753F07CQ46610157-484A79B4-C4F3-40F4-AF2B-FBF01D57CD99Q46923390-AAB092BD-56BC-454F-BD3B-45AEFE0CE26EQ47600240-F8207460-4E2E-485A-8F92-444B94453409Q47738183-C2415AA9-86CA-45B6-B49F-ADB0C1A2660AQ47940591-A51BEA76-4047-4EF5-AB64-C033993D17B2Q48298593-D3D1391A-8CDB-4A8E-A4CB-5166B4CED4B8Q48635567-AA43B081-8C40-47E7-964A-373C8D97772CQ48735360-6C354786-B708-4E42-879F-BCA4EDAC636AQ48861632-429C6CB5-D887-43B7-A5A8-DF2E477E1C96Q48945974-7F748B6F-2379-45F4-AB60-417D92933DB3Q49122241-C529DB10-1235-4AA3-B7A1-61EE0B685458Q51486989-EE9EC704-4BF3-4087-AC8F-FA616FDEE38AQ60777185-B3D1BD65-FCCE-406F-9167-ED77E4251A8EQ60777196-A9E35A2C-DFFF-4D23-9B21-84989440C523Q86972894-1A767BA6-D5F3-4DCC-B94C-C30FCAC74889Q90614231-D830285C-5FCC-4C64-86A5-FE8AC3CE3549
P50
description
forskare, farmakologi
@sv
researcher, pharmacology
@en
name
Markus M Forsberg
@ast
Markus M Forsberg
@en
Markus M Forsberg
@fi
Markus M Forsberg
@nb
Markus M Forsberg
@nl
Markus M Forsberg
@sv
type
label
Markus M Forsberg
@ast
Markus M Forsberg
@en
Markus M Forsberg
@fi
Markus M Forsberg
@nb
Markus M Forsberg
@nl
Markus M Forsberg
@sv
prefLabel
Markus M Forsberg
@ast
Markus M Forsberg
@en
Markus M Forsberg
@fi
Markus M Forsberg
@nb
Markus M Forsberg
@nl
Markus M Forsberg
@sv
P31
P496
0000-0002-0335-8142